Insilico Medicine has entered a collaboration with SK, valued at up to $2.5 billion, to develop therapies for neuroimmune indications. The deal leverages Insilico's Pharma.AI platform, which integrates target validation, generative chemistry, and molecule optimization, to discover and design candidates against targets selected by SK.
Under the agreement, Insilico will conduct preclinical discovery and optimization, while SK will steer late-stage development and global commercialization. The partnership focuses on neuroimmune disorders, a category where few effective treatments exist, merging AI-driven drug design with SK's clinical expertise.
Financial details beyond the headline figure were not disclosed. The $2.5 billion total includes upfront payments, milestone payments, and potential royalties, but the precise breakdown remains confidential. No specific targets or timelines have been announced.
The collaboration underscores a growing trend of big pharma partnering with AI-native biotechs. For Insilico, it validates its platform's applicability beyond oncology and fibrosis. SK gains access to a validated AI engine to replenish its pipeline in a high-need therapeutic area.
This deal faces typical risks of early-stage AI collaborations: high failure rates of preclinical candidates and challenges in translating computational predictions into clinical success. No clinical data from prior Insilico programs was referenced in the announcement.